Searchable abstracts of presentations at key conferences in endocrinology

ea0093oc20 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

ROR-1 specific CAR-T cells with CRISPR/CAS9 mediated glucocorticoid receptor-knockout exert potent antitumor efficacy in advanced adrenocortical carcinoma

Schauer Marc Philipp , Altieri Barbara , Redondo-Frutos Rodrigo A , Spieler Peter , Maier Tanja , Oppelt Daniel , Kroiss Matthias , Sbiera Silviu , Weber Justus , Fassnacht Martin , Landwehr Laura-Sophie , Hudecek Michael

# These authors contributed equallyIntroduction: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy with poor prognosis and limited treatment options. In addition, ACC is characterized by endogenous glucocorticoid (GC) excess in 60% of cases which is hypothesized to be one reason, why first clinical trials evaluating the potency of immune checkpoint blockade showed only modest results. Here, we report the identificati...

ea0099oc7.1 | Oral Communications 7: Endocrine-related Cancer | ECE2024

CRISPR/Cas9-mediated glucocorticoid receptor knockout effectively enhances antitumor efficacy of ROR1 specific CAR-T cells in advanced adrenocortical carcinoma

Schauer Marc Philipp , Weber Justus , Landwehr Laura-Sophie , Spieler Peter , Altieri Barbara , Maier Tanja , Kroiss Matthias , Kircher Stefan , Kurlbaum Max , Tony Liz , Sbiera Silviu , Fassnacht Martin , Hudecek Michael

Background: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy with poor prognosis and very limited treatment options in advanced disease. The only curative approach is complete surgical resection. Additionally, 60% of patients show endogenous glucocorticoid (GC) excess with clinical apparent hypercortisolism and low to no immune cell infiltration. To date, no therapeutically relevant surface markers are known for ACC, which is why it has not been con...